Clinical Trials Directory

Trials / Completed

CompletedNCT00319670

A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
25 (planned)
Sponsor
Braintree Laboratories · Industry
Sex
All
Age
4 Years – 16 Years
Healthy volunteers
Not accepted

Summary

To evaluate patient acceptance of a new MiraLax dose formulation in children currently treated with polyethylene glycol 3350 powder for treatment of constipation.

Detailed description

To evaluate patient acceptance of a new MiraLax dose formulation in children currently treated with polyethylene glycol 3350 powder for treatment of constipation.

Conditions

Interventions

TypeNameDescription
DRUGMiraLax

Timeline

Start date
2006-03-01
Primary completion
2006-05-01
First posted
2006-04-27
Last updated
2013-02-07

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00319670. Inclusion in this directory is not an endorsement.